[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100415606":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":33,"locations":43,"responsibleParty":63,"collaborators":65,"id":69,"slug":38,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":38,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":38,"enrollmentInfo":77,"targetDuration":38,"studyType":80,"phases":81,"briefSummary":84,"conditions":85,"keywords":38,"overallStatus":46,"whyStopped":38,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Abramson Cancer Center at Penn Medicine","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Atezolizumab and Tocilizumab","EXPERIMENTAL","Participants receive Atezolizumab 1200mg IV and Tocilizumab 6mg\u002Fkg IV (or Tocilizumab 4mg\u002Fkg IV) every 21 days",[13,14],"Drug: Atezolizumab","Drug: Tocilizumab",[16,23],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","Atezolizumab","1200mg infusion",[9],[22],"Tecentriq",{"type":17,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"Tocilizumab","Tocilizumab 6mg\u002Fkg or 4mg\u002Fkg infusion",[9],[28],"Actemra, RoActemra, RO4877533",[30],{"name":31,"affiliation":5,"role":32},"Melina Marmarelis, MD, MSCE","PRINCIPAL_INVESTIGATOR",[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Melissa Volpe, BA","CONTACT","215-220-9703",null,"melissa.volpe@pennmedicine.upenn.edu",{"name":31,"role":36,"phone":41,"phoneExt":38,"email":42},"215-615-5835","melina.marmarelis@pennmedicine.upenn.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Abramson Cancer Center of the University of Pennsylvania","RECRUITING","Philadelphia","Pennsylvania","19104","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-75.16362,39.95238,{"lat":56,"lon":55},[59,62],{"name":60,"role":36,"phone":37,"phoneExt":38,"email":61},"Mel V, BA","Melissa.volpe@pennmedicine.upenn.edu",{"name":31,"role":32,"phone":38,"phoneExt":38,"email":38},{"type":64,"investigatorFullName":38,"investigatorTitle":38,"investigatorAffiliation":38,"oldNameTitle":38,"oldOrganization":38},"SPONSOR",[66],{"name":67,"class":68},"Genentech, Inc.","INDUSTRY","100415606",false,"NCT04691817","Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy","Inclusion Criteria:\n\n* Advanced non-squamous NSCLC (Stage IV or recurrent after initial curative intent therapy) in adults age 18 or older\n* Prior exposure to at least 1 line of therapy\n* Exposure to a including checkpoint inhibitor in line of therapy immediately prior to enrollment on trial\n* ECOG PS 0-2\n\nExclusion Criteria:\n\n* Presence of a driver mutation that is susceptible to targeted therapy\n* No greater than CTCAE v5 grade 3 toxicity attributed to prior immunotherapy\n* Other active invasive malignancy requiring ongoing therapy\n* Evidence of progressing or untreated brain metastases\n* Evidence or history of leptomeningeal disease\n* Uncontrolled tumor related pain\n* History of an autoimmune disease or IPF","ALL","18 Years",{"count":78,"type":79},28,"ESTIMATED","INTERVENTIONAL",[82,83],"PHASE1","PHASE2","This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.",[86],"Lung Cancer, Nonsmall Cell","2026-01-06",{"date":89,"type":90},"2026-01-07","ACTUAL",{"date":92,"type":90},"2023-07-25",{"date":94,"type":79},"2027-09",{"name":5,"class":6},1]